Asphaug L, Akslen LA, Blix ES, Boge B, Borgen EF, Brekke MB, Falk RS, Geitvik GA, Gilje B, Gravdehaug B, Heie A, Janssen E, Kiserud CE, Kursetgjerde T, Langerød A, Lømo J, Mannsåker B, Mortensen E, Olsson P, Porojnicu AC, Raj SX, Roe OD, Russnes HEG, Skjerven HK, Songe-Møller S et al. (2025)
Cost-effectiveness of Prosigna for Adjuvant Treatment Decisions in Early Breast Cancer: Healthcare Sector and Societal Perspectives
Clin Breast Cancer, 25 (6), e721-e730
DOI 10.1016/j.clbc.2025.04.011, PubMed 40348620

Fjørtoft MO, Garred Ø, Lingjærde OC, Lande KT, Ottestad L, Bergheim IR, OSBREAC, Lømo J, LaMont C, Myklebust JH, Russnes H, Huse K, Rye IH (2025)
Single-cell analysis reveals tumour size as a key driver of immune cell profile alterations in primary breast tumours and corresponding lymph nodes
BJC Rep, 3 (1), 35
DOI 10.1038/s44276-025-00152-3, PubMed 40394379

Haj Mohammad SF, van der Pol H, Vrdoljak E, Lassen U, Ojamaa K, Jalkanen K, Verlingue L, Stenzinger A, Patócs A, Curigliano G, Baltruškevičienė E, Helland Å, Russnes HG, Ługowska I, Mainoli B, Edsjö A, Lonardi E, Taskén K, Gelderblom H (2025)
A comprehensive assessment of the existing landscape of personalized cancer medicine in the European Union, on behalf of the PCM4EU consortium
ESMO Open, 10 (11), 105872 (in press)
DOI 10.1016/j.esmoop.2025.105872, PubMed 41197434